Compare ALLT & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALLT | CCCC |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 429.1M | 240.3M |
| IPO Year | 2006 | 2020 |
| Metric | ALLT | CCCC |
|---|---|---|
| Price | $9.83 | $2.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $12.75 | $8.50 |
| AVG Volume (30 Days) | 445.1K | ★ 1.4M |
| Earning Date | 11-20-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $98,512,000.00 | $30,108,000.00 |
| Revenue This Year | $12.44 | N/A |
| Revenue Next Year | $12.98 | N/A |
| P/E Ratio | $460.39 | ★ N/A |
| Revenue Growth | ★ 7.51 | N/A |
| 52 Week Low | $4.37 | $1.09 |
| 52 Week High | $11.42 | $4.70 |
| Indicator | ALLT | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 55.96 | 49.03 |
| Support Level | $9.68 | $2.50 |
| Resistance Level | $10.35 | $2.69 |
| Average True Range (ATR) | 0.39 | 0.18 |
| MACD | 0.10 | -0.01 |
| Stochastic Oscillator | 62.50 | 23.86 |
Allot Ltd is a provider of network intelligence and security solutions for service providers and enterprises. The company's solutions are deployed globally for network and application analytics, traffic control and shaping, and network-based security services. The firm's multi-service platforms are deployed by mobile, fixed, and cloud service providers and enterprises. The company has a customer base in Europe, Asia and Oceania, the Americas, the Middle East, and Africa.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.